Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHGDH | O43175 | 16/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19343198 | 1.00 | PHGDH (0.80) | PHGDHKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL19343164 | 0.93 | PHGDH (0.77) | PHGDHKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL19343203 | 0.92 | PHGDH (0.76) | PHGDHKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL19343437 | 0.91 | PHGDH (0.75) | PHGDHKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL30339583 | 0.91 | PHGDH (0.66) | PHGDHKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL19343577 | 0.91 | PHGDH (0.66) | PHGDHKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL30339239 | 0.89 | PHGDH (1.00) | PHGDHKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL19331467 | 0.89 | PHGDH (1.00) | PHGDHKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL19343476 | 0.88 | PHGDH (0.71) | PHGDHKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL25153892 | 0.88 | PHGDH (0.67) | PHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312536-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11634412-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2023-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634412-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | PHGDH, G6PD, PGD | PHGDH 1/4885KDM4E 2482/4885ALDH1A1 222/4885 |
| US-20230312536-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | PHGDH, G6PD, PGD | PHGDH 1/4885KDM4E 2482/4885ALDH1A1 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.